Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bio-Techne Cp (TECH)

Bio-Techne Cp (TECH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,320,525
  • Shares Outstanding, K 38,556
  • Annual Sales, $ 738,690 K
  • Annual Income, $ 229,300 K
  • 60-Month Beta 0.98
  • Price/Sales 12.12
  • Price/Cash Flow 37.77
  • Price/Book 6.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.00
  • Number of Estimates 2
  • High Estimate 1.04
  • Low Estimate 0.97
  • Prior Year 0.88
  • Growth Rate Est. (year over year) +13.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
228.66 +5.72%
on 09/24/20
262.25 -7.82%
on 09/02/20
-9.18 (-3.66%)
since 08/25/20
3-Month
228.66 +5.72%
on 09/24/20
286.68 -15.68%
on 07/20/20
-16.53 (-6.40%)
since 06/25/20
52-Week
155.17 +55.79%
on 03/23/20
286.68 -15.68%
on 07/20/20
+40.24 (+19.97%)
since 09/25/19

Most Recent Stories

More News
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

BMY : 59.49 (+2.13%)
EBS : 101.63 (+2.54%)
TECH : 241.74 (+4.10%)
BLUE : 57.04 (+2.46%)
Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled (available ). Principal investigator Dr. , Professor of Urology at , and colleagues...

TECH : 241.74 (+4.10%)
Downtrend Call Working As Bio-Techne Corp Stock Falls 8.8% (TECH)

SmarTrend identified a Downtrend for Bio-Techne Corp (NASDAQ:TECH) on August 20th, 2020 at $258.94. In approximately 1 month, Bio-Techne Corp has returned 8.82% as of today's recent price of $236.11.

TECH : 241.74 (+4.10%)
Alexion's New Formulation of Ultomiris Gets CHMP Backing

Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.

ALXN : 114.43 (+2.15%)
EBS : 101.63 (+2.54%)
ALIM : 5.05 (unch)
TECH : 241.74 (+4.10%)
Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection...

TECH : 241.74 (+4.10%)
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

AGEN : 4.02 (+2.03%)
EBS : 101.63 (+2.54%)
ALIM : 5.05 (unch)
TECH : 241.74 (+4.10%)
Immunomedics Releases Trodelvy Data From Cancer Studies

Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.

IMMU : 85.36 (+0.07%)
EBS : 101.63 (+2.54%)
ALIM : 5.05 (unch)
TECH : 241.74 (+4.10%)
Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary...

TECH : 241.74 (+4.10%)
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA

The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.

RHHBY : 44.8200 (+0.27%)
EBS : 101.63 (+2.54%)
CCXI : 52.74 (+2.01%)
TECH : 241.74 (+4.10%)
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.

RDY : 69.60 (+2.72%)
BMY : 59.49 (+2.13%)
EBS : 101.63 (+2.54%)
TECH : 241.74 (+4.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade TECH with:

Business Summary

Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising...

See More

Key Turning Points

2nd Resistance Point 250.01
1st Resistance Point 245.88
Last Price 241.74
1st Support Level 233.98
2nd Support Level 226.21

See More

52-Week High 286.68
Last Price 241.74
Fibonacci 61.8% 236.44
Fibonacci 50% 220.92
Fibonacci 38.2% 205.41
52-Week Low 155.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar